Overview

A Study of the Effectiveness in Patients With Gastric or Gastroesophageal Junction Cancer With Nivolumab by Itself or in Combination With Ipilimumab and in Patients With Esophageal Cancer With Combination of Nivolumab and Ipilimumab.

Status:
Not yet recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The main purpose of this study for patients with gastric or gastroesophageal cancer is to evaluate how well the tumor is responding to treatment with nivolumab by itself, or in combination with ipilimumab. For patients with esophageal cancer, the main purpose is to evaluate how well the tumor is responding to treatment with the combination of nivolumab and ipilimumab.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Ono Pharmaceutical Co. Ltd

Treatments:

Antibodies, Monoclonal
Nivolumab